Gain new key opinion leader (KOL) insights on the latest events happening in T2DM. Topics covered include; expert views on Novo Nordisk’s recently approved once-weekly GLP-1 agonist, semaglutide (Ozempic); opinions on the results of the Phase IIIb/IV EXSCEL study which is assessing the cardiovascular (CV) risk of AstraZeneca’s Bydureon (exenatide extended release) in T2DM patients; and views on Zafgen’s ZGN-1061, a fumagillin-class, injectable small molecule second generation MetAP2 inhibitor, which recently entered Phase II clinical development.
Do KOLs perceive semaglutide to have any advantages over other once-weekly GLP-1 agonists?
What is KOL perception of semaglutide’s safety profile?
Where do experts see this semaglutide fitting into the treatment algorithm?
How do KOLs view the results of the EXSCEL study and will it impact prescribing of Bydureon?
Do KOLs raise any new safety concerns based on the findings of the EXSCEL study?
What strategies do experts suggest for growing Bydureon’s market share?
How do KOLs perceive ZGN-1061’s mechanism of action?
How do KOLs view ZGN-1061’s subcutaneous mode of delivery?
Where do KOLs see ZGN-1061 fitting into the T2DM treatment algorithm?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook